

## BAUSCH HEALTH MODERN SLAVERY STATEMENT

This Modern Slavery Statement has been prepared on behalf of Bausch Health Companies Inc. and Solta Medical Corporation (the 'Company') for the period of 1 January 2025 through 31 December 2025. This statement sets out the steps that the Company has taken to mitigate the risk of modern slavery occurring in our business or our supply chain.

This statement is intended to satisfy the requirements of Canada's *Fighting Against Forced Labour and Child Labour in Supply Chains Act*, the *California Transparency in Supply Chains Act*, and similar other legislation that may apply to the Company in other markets (collectively, the "Supply Chain Transparency Legislation").

We believe in the fundamental respect for human rights of all stakeholders and local communities in which the Company conducts business. We fully support the intent of the Supply Chain Transparency Legislation, and we oppose human trafficking and slavery in all forms. We work to the highest professional standards to ensure that we comply with all laws and regulations applicable to the Company.

The Company is committed taking appropriate steps to tackle modern slavery (including slavery, servitude, forced or compulsory labor and human trafficking), both within our own organization and within our external supply chain. We expect our suppliers to conduct business abiding by all applicable laws, rules, and regulations. We also monitor our labor force and supply chains to identify and rectify any areas of concern, which may include terminating business relationships with organizations that knowingly engaged in practices that constitute modern slavery.

No human rights violations by the Company or any director, officer, employee, or person doing business on our behalf will be tolerated. All employees have an obligation to conduct business with integrity, including respecting human rights.

### 1. Description of the Organization's Structure, Activities and Supply Chains

Bausch Health Companies Inc. is a global diversified pharmaceutical company enriching lives through our relentless drive to deliver better health outcomes. We develop, manufacture and market a range of products, primarily in gastroenterology, hepatology, neurology, dermatology, medical aesthetic devices, international pharmaceuticals, and eye health, through our controlling interest in Bausch + Lomb. Our ambition is to be a globally integrated healthcare company, trusted and valued by patients, HCPs, employees and investors.

Bausch Health Companies Inc. is listed on the New York Stock Exchange and Toronto Stock Exchange. In Canada, the Company also operates under Bausch Health, Canada Inc. The Company's Canadian head office is located in Laval in the province of Québec. The US headquarters are located in Bridgewater, New Jersey. The Company employs approximately 881 employees in Canada and approximately 1,721 employees in the United States as of the date of this report and globally, a total of approximately 7177 employees.

Bausch Health in Canada operates two manufacturing sites for Pharmaceutical Drug Products, which we sell in Canada and Worldwide. One facility is located in Laval QC and one in Steinbach

MB. We also import finished dosage forms from Contract Manufacturers to sell in Canada, the United States and elsewhere. These products are manufactured in various foreign markets. Our Aesthetic Medical Devices are produced primarily in our factory in Bothell, Washington.

For our pharmaceutical internal manufacturing operations, we procure Active Pharmaceutical Ingredients and excipients from various well-established manufacturers, qualified by relevant government authorities, and located all around the world. Packaging components such as bottles, cartons, and boxes are sourced principally from Canadian and US manufacturers who have relevant ISO certifications.

We also subcontract the manufacturing of certain Drug Products, which we then import and sell in Canada and/or the United States. Some of the Drug Products dossiers belong to the Company, while others are licensed from contract manufacturers. We buy from large contract manufacturing organizations who, aside from the Company's oversight, are also regularly audited by competent government authorities including Health Canada and the FDA.

Lastly, for our SOLTA aesthetic device business, we procure electro-mechanical components mostly from suppliers located in the United States, with electronic components sourced primarily from Asia.

We have undertaken a risk-based approach to managing human rights risks in our supply chain, which focuses primarily on the Company's direct suppliers. In 2025, this approach was extended to include an assessment of our key indirect suppliers with annual spend exceeding USD\$1 million. Building on this progress, we plan to further expand monitoring of human rights risks across the indirect spend, including categories such as lab supplies, services, or spare parts, which generally represent lower risks versus direct spend.

Section 3 below explains our due diligence process in relation to forced labor and child labor for the direct spend suppliers from whom we buy Active Pharmaceutical Ingredients, Excipients, Packaging, Electro-Mechanical components and Contract Manufacturing services in connection with our manufacturing and sale of Drug Products and SOLTA Aesthetic Devices.

## 2. Policies in Relation to Forced Labor and Child Labor

As a leading specialty pharmaceutical company, we are steadfastly committed to doing the right thing for patients, for our employees, and for our communities. We have developed and implemented comprehensive policies that are designed to mitigate modern slavery risks, including but not limited to:

- The Bausch Health [Code of Conduct](#), with a dedicated section on Human Rights and Modern Slavery;
- [Supplier Standards of Conduct](#);
- [Business Ethics Reporting Policy](#);
- [Global Anti-Bribery Policy](#); and
- [Global Human Rights Policy](#);

These policies apply to all Company's employees, officers, and directors. All employees complete mandatory training on our Code of Conduct on an annual basis. The training includes a section on human rights that advises employees about the risks of forced labor and child labor, as well as the mechanisms for reporting any potential violations.

The Company is committed to adhering to the highest standards of ethics and integrity in all our interactions with patients, healthcare providers, customers, fellow colleagues and other key stakeholders. The Company vigorously enforces these policies and will take prompt and appropriate action, up to and including termination of employment or other relationships, of those found to be in violation.

We are committed to conducting our business activities in compliance with human rights laws globally and adhering to the basic human rights principles outlined in the United Nations Universal Declaration on Human Rights. In accordance with our global Code of Conduct, we respect internationally protected human rights and demand fair and respectful treatment of people inside and outside the Company. Our standards are also consistent with:

- The International Labor Organization (ILO) Declaration on Fundamental Principles and Rights at Work, and
- The OECD Guidelines for Multinational Enterprises.

In addition, in most countries where the Company conducts business, there are relevant local laws that overlap with our international human rights requirements, including criminal laws and laws regarding child labor, freedom of association, equality of economic opportunity, accessibility and accommodation, and compensation. We will adhere to such applicable local laws and international requirements. In the event of potential conflicts arising between internationally recognized human rights and national legislation in the countries in which we operate, we are committed to the highest ethical standards in compliance with all applicable laws and internal rules and procedures.

### **3. Due Diligence Processes in Relation to Forced Labor and Child Labor**

Bausch Health Companies Inc. is a life sciences company that follows pharmaceutical good manufacturing practice ("GMP"), relevant ISO standards, and all applicable regulations pertaining to its pharmaceutical and medical device development, manufacturing, sales, and marketing activities. These include strong supplier quality management processes for all direct materials suppliers to ensure they follow all applicable laws.

We use five processes in our supply chain due diligence to evaluate, monitor and prevent modern slavery among our direct suppliers:

- Our oversight starts with our quality management system, which includes regular audits of Direct Material suppliers where our auditors are trained to identify and escalate potential modern slavery violations. Audit frequency and supplier selection is determined according to good manufacturing practice "GMP" and relevant medical devices rules. Audits can be for surveillance, qualification, or for cause. The Company may conduct these audits directly or it may use a third party.

- Our Master Services and Supply Agreements with third party suppliers include provisions requiring compliance with all applicable laws, rules, and regulations as well as with our internal policies such as our Code of Conduct (including its human rights provisions) and Global Anti-Bribery Policy. We supplemented these policies with a Supplier Code of Conduct, which reinforces our requirements regarding the protection of human rights.
- When the Company procures goods or services via a purchase order, the documentation includes our standard [Terms and Conditions](#), which require the supplier to warrant that all goods and/or services have been produced or performed in compliance with all applicable laws and regulations, including human rights laws and regulations.
- We utilize a risk alert tool that monitors our key direct suppliers for supply chain disruptions and compliance with labor practices and human rights standards. This tool notifies procurement team responsible if a supplier is involved in enforcement investigations, litigation, or negative news related to potential labor or human rights violations. No material issues were identified during the reporting period of 2025 related to forced and child labor.
- We utilize functionality in SAP that allows us to identify and automatically block any supplier that appears on a sanctioned list, including sanctions arising from human rights violations. The system automatically blocks the creation of any purchase order, meaning we cannot buy anything from such vendor.

We analyze direct suppliers who provide goods and services related to the Active Drug Products we sell in Canada and the United States, which are either made in our internal plants or purchased as finished products from contract manufacturers. As of December 31, 2024, all of our strategic direct suppliers are actively monitored in our risk alert tool and the majority operate under supply agreements that contain our current terms and conditions. We continue to expand, negotiating supply agreements with additional suppliers.. All suppliers receive the latest [Terms and Conditions](#) with any new purchase orders, and they are all screened against our sanction screening tools.

We prioritize our supplier oversight efforts based on several factors, one of which is the geography in which each supplier operates. Most of our Active Pharmaceutical Ingredients are sourced from the EU, US, and Canada where modern slavery risk is less prevalent than in certain developing markets. We do not have suppliers in top 10 countries with most prevalent Modern Slavery risk as per [Global Slavery Index | Walk Free](#). However, we extended our Modern Slavery risk analysis to countries such as India, China, Malaysia, Taiwan, Vietnam and South Korea where we buy some Direct Materials. We have conducted additional diligence on these entities to confirm that they comply with Good Manufacturing Practice GMP, that they have adequate internal policies addressing modern slavery risks, that they are not subject to sanctions, and that they have a reputation for behaving in a manner consistent with our standards.

In January 2024 we have launched our [Responsible Procurement Program](#) to further enhance our supply chain due diligence processes and to identify emerging risks and work upfront with our suppliers on any identified gaps. We have engaged the services of a global Corporate Social Responsibility rating company called “EcoVadis” and starting March 2024 are conducting individual sustainability performance assessments of our supply chain partners, that include labor and human rights topics. Once we obtain the results of individual assessments, we analyze

suppliers with low scores in Labor and Human Rights area, as defined in our Responsible Procurement SOP, and request corrective actions for identified improvement areas. In addition, we monitor EcoVadis 360 Watch Negative Findings to identify forced labor and child labor risks. This initiative is an integral component of the Bausch Health Environmental Social and Governance (ESG) compliance program, and we expect all suppliers (in phases) to undertake the assessment.

#### 4. Addressing non-conformance - Forced Labor and Child Labor

Within our existing supplier base, we believe that our suppliers located in developing markets carry a higher risk of human rights violations than those who operate in other markets from which we source products (generally Canada, the United States and Western Europe). We are cognizant of recent examples of human rights violations in the Asian IT Hardware and Clothing industries, amongst others. We also consider that the Chemical and Electronic Industries in which many of our suppliers operate have a heightened risk profile (see e.g., [Global Slavery Index | Walk Free](#)) since they might use lower skilled and more vulnerable members of the workforce. We are also cognizant that entities operating in a lower-risk geography market might incorporate goods or services from downstream supply chain suppliers located in higher risk countries or regions.

The 2025 assessment of modern slavery risk among our direct suppliers for products sold in Canada and the USA has been completed, with corrective actions assigned where warranted. We believe that we have undertaken appropriate actions to mitigate the risk of modern slavery among these entities, as well as among others in our operations. When compared to the previous year 2024:

- The score has improved for 26% of direct suppliers in scope for Modern Slavery assessment;
- 44% of direct suppliers have corrective actions in progress; and
- 30% of direct suppliers are new and no assessment has been made yet.

However, we are committed to further strengthening our due diligence process in 2026 and beyond. Our 2026 initiative includes expanding our use of the EcoVadis tool to include all direct suppliers and more indirect suppliers based on risk analysis.

#### 5. Grievance Mechanisms and Remediation

Our [Business Ethics Reporting Policy](#) is designed to make it easy for reporters to make disclosures, without fear of any detrimental treatment. The Company maintains an independent Hotline that allows its employees worldwide to provide a confidential way to raise concerns about unethical conduct, including those related to supply chain. It consists of toll-free telephone lines that are available anytime — 24 hours a day, seven days a week in over 100 languages, and an online reporting service at <https://hotline.bauschhealth.com>. It is operated by an external independent firm. Concerns may be raised anonymously.

The scope of the hotline covers all corporate values and principles of our [Code of Conduct](#), including human rights and modern slavery matters, in accordance with the applicable legislation in each country. The hotline is available to suppliers and external stakeholders within each market in which we operate.

Complaints received via the hotline are handled according to an established process. After submitting a report through the vendor's website, complainants automatically receive an acknowledgment of receipt, as well as a report key and password that allows them to track the status of their complaint at any time.

All cases reported via the hotline will be investigated. The complainants can be contacted for this purpose if they have agreed to be contacted. Depending on the severity of the case, appropriate action will be taken. Confidentiality is guaranteed, along with protection against discrimination or punishment for those who submit reports in good faith.

## **6. Training and Awareness**

Building our capacity to understand human rights and modern slavery challenges is important to our human rights approach. All employees are provided with mandatory training on [Code of Conduct](#) which includes information on human rights and how to report concerns. We aim to expand training opportunities as our program develops.

## **7. Effectiveness of Measures Taken**

We periodically identify the need for suppliers to take corrective actions. Progress of corrective actions is being monitored continuously. We have not found any credible evidence that the identified high-risk suppliers have violated forced or child labor laws within our supply chain, nor have we received grievances from internal or external stakeholders. We have not identified any loss of income to vulnerable families resulting from measures taken to eliminate the use of forced labor or child labor in our activities and supply chains.

## **8. Conclusion**

The Company is committed to maintaining the highest standards for the protection of human rights, as well as preserving the health and safety of our value chain workers. We expect the same from our suppliers. The Company continually reviews its processes and policies to help ensure we effectively mitigate all modern slavery, human trafficking and related risks.

**Attestation and Approval:**


*This Report was approved on May 13, 2026, pursuant to subparagraph 11(4)(b)(ii) of the Fighting Against Forced Labor and Child Labor in Supply Chains Act by the board of directors of Bausch Health Companies Inc. on its own behalf and as the entity that directly controls Solta Medical Corporation.*

*I make this attestation in my capacity as Chief Executive Officer of Bausch Health Companies Inc. for and on behalf of the board of Bausch Health Companies Inc.*

*Name:* Thomas J. Appio

*Title:* Chief Executive Officer

*I have the authority to bind Bausch Health Companies Inc.*



---

**Date:** May 13, 2026